Biosimilars Packaging Webinar 
Safe Biologics
DECEMBER 3, 2023
ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.
Safe Biologics
NOVEMBER 12, 2023
View the full webinar here or watch individual segments linked below. 6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. However, S.6
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
JUNE 23, 2025
But Stelara, which became a megablockbuster in 2023, will leave a revenue gap that J&J has yet to fill as biosimilar competition heats up. In 2024, Johnson & Johnson became the first pharma with two megablockbusters: its immunology drug Stelara and an oncology therapy Darzalex. Is DTC pharma advertising coming to an end?
Safe Biologics
DECEMBER 6, 2023
prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”
pharmaphorum
JUNE 27, 2025
Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
Pharma Marketing Network
DECEMBER 4, 2024
Add to that the competition from generics and biosimilars, and the stakes couldn’t be higher. Highlight your commitment to eco-friendly practices, from reducing packaging waste to sourcing ethically. Using email, social media, in-person meetings, and webinars to deliver a consistent message across platforms.
Pharmaceutical Technology
JULY 4, 2025
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). Clinical trials have demonstrated that both biosimilars match the reference product’s safety, quality and efficacy standards. How will RFK Jr’s American dream for vaccines play out?
Expert insights. Personalized for you.
130 
Let's personalize your content